AbstractPsychedelic-assisted interventions are complex, context-sensitive interventions in which pharmacological, psychological, relational, environmental, cultural, and temporal processes interact. Trials of psilocybin and related compounds have reported promising but heterogeneous findings across psychiatric, substance-use, and existential indications, while also revealing challenges related...
PTSD is a prevalent and debilitating condition, for which many individuals do not seek or complete treatment. As new PTSD treatments are being evaluated, such as psychedelic-assisted therapies, it’s important to understand the preferences of individuals for whom these treatments are being developed. To date, no research has directly compared preferences for psychedelic-assisted therapies...
Dissociative psychoactive substances (such as ketamine and PCP) present a challenge to standard models of altered states of consciousness. Unlike classical hallucinogens which enrich or distort conscious content, dissociatives induce a peculiar fragility in the construction of one’s world-model – a breakdown of the high-level coherence that ordinarily binds perception, selfhood, and meaning....
Current psychiatric models, while clinically valuable, remain limited in their ability to account for the complexity, variability, and context dependence of mental disorders. Converging evidence from neuroscience, complexity science, and psychedelic research suggests that psychiatric symptoms may be better understood as stable patterns of organization within dynamic, multilevel systems rather...
Bipolar II disorder (BD-II) is characterised by hypomanic and depressive episodes with the latter tending to dominate the clinical course of the disorder, and they are often associated with suicidality. Despite available guideline-based recommendations for first-line pharmacological treatments, patient outcomes remain suboptimal, especially for those with chronic depression and suicidal...
Abstract Background Research on psilocybin's antidepressant effects has been investigated rigorously over the last 20 years. Psilocybin has been used in both major depressive disorder (MDD) and treatment resistant depression (TRD) cohort with promising results. Aims The aim of this review was to summarize the reporting practices used in psilocybin-assisted therapy (PAT) trials for MDD and TRD....
Australia became the first country to establish a national regulatory pathway permitting authorised psychiatrists to prescribe 3,4-methylenedioxymethamphetamine (MDMA) for post-traumatic stress disorder (PTSD) and psilocybin for treatment-resistant depression (TRD) through the Therapeutic Goods Administration (TGA) Authorised Prescriber Scheme. Two and a half years after implementation,...
A resurgent therapeutic frontier, the contemporary renaissance in psychedelic science has accelerated investigation of classic serotonergic psychedelics (psilocybin, lysergic acid diethylamide (LSD), N,N-dimethyltryptamine (DMT), mescaline), empathogenic entactogenic agents (3,4-methylenedioxymethamphetamine (MDMA)), and glutamatergic dissociatives (ketamine) as adjuncts to psychotherapy. While...
High Resolution Image Download MS PowerPoint Slide The psychedelic therapeutics field continues to evolve beyond classical hallucinogens toward integrated treatment platforms that combine optimized pharmacology, drug delivery, and clinical implementation. Recent patent applications disclose selective 5-HT2A receptor activators, precision aerosol delivery technologies for psychedelic compounds,...
Open Science FrameworkJuly 9, 2026Raul Edison Luna Lazo, Nicole Milagritos Cardoso Azorza, Jatziri Yanina Vilca Yanac et al.
preprint
Obsessive-compulsive disorder (OCD) is a chronic neuropsychiatric condition characterized by intrusive thoughts and repetitive behaviors that cause distress and functional impairment worldwide. Although selective serotonin reuptake inhibitors and cognitive behavioral therapy are first-line treatments, a considerable proportion of patients show an insufficient response, supporting the need for...